Skip to main content
. 2019 May 15;11(5):2784–2800.

Figure 2.

Figure 2

FAT4 protein expression in EC tissues. A: Immunohistochemical staining of FAT4, USP51, LATS1/2 and YAP in EC tissues, noncancerous tissues and normal tissues. Original magnification, × 100 and × 400, scale bar = 100 μm and 50 μm, respectively. B: Proportions of samples negative (- or +) or positive (++ or +++) for FAT4, USP51, LATS1/2 and YAP among 116 EC tissues (EC) and 120 normal tissues (NT). C: EC patients with low expression of FAT4 exhibited worse overall survival compared with patients with high expression of FAT4 (**P<0.01, Log rank test). Kaplan-Meier method was used to draw the cumulative survival curves. D: The correlations of the scores for the four molecules, FAT4, USP51, LATS1/2 and YAP, were measured by Pearson’s coefficient. E: The core components of the Hippo signalling pathway, including LATS1, LATS2, TAZ and YAP. LATS1, LATS2 and YAP mRNA expression was downregulated in 552 tumour samples compared with 35 noncancerous samples, as revealed by the TCGA RNA-Seq analysis, while TAZ showed the opposite trend (*P<0.05, ***P<0.0001, t test).